Case studies
Financial statements
of scientific expertise
Patents held by customers
Campuses
Active customers
(430 Mn USD) Revenue from operations in FY25
Profit After Tax in FY25#
of world-class R&D and manufacturing
Scientists
Total workforce (as of March 31, 2025)
Total hazardous and non-hazardous waste recycled
Power sourced from renewable energy
# Before exceptional items 1 USD = Rs 84.65
We combine cutting-edge science with a deep understanding of customer needs to drive innovation. Our commitment to service, quality and excellence is embedded in every aspect of our operations, fostering trust, confidentiality, and seamless collaboration.
At Syngene, our
purpose goes beyond science. We are building a resilient, inclusive, and
values-driven organization where people thrive and innovation flourishes. FY25 was a
year of alignment between vision and action, with investments in wellbeing, equity,
and sustainability reinforcing our commitment to long-term value creation for all
stakeholders.
Syngene is well
positioned for accelerating growth and transformation, with the potential to become
a leader in serving the global biopharma and wider life sciences outsourcing
market models.
Despite
sectoral headwinds, Syngene delivered resilient performance with strong cash
generation of Rs 1,168 Cr, fully funding our USD 85 Mn capex including a strategic
U.S. biologics facility acquisition, thus positioning us for long-term growth in the
high-potential CRDMO market.
Provide an integrated end-to-end therapeutic discovery services encompassing drug discovery, pre-clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.
We are an integrated research, development and manufacturing organization providing scientific services from early discovery to commercial supply. We serve a wide range of industrial sectors including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical companies.
Scientific rigor and cross-functional collaboration propelled the advancement of discovery programs across multiple therapeutic areas.
Our long-standing collaborations with pharmaceutical leaders exemplify our commitment to scientific rigor, operational excellence, and shared success.
We focus on advancing small molecules and next-gen modalities like ADCs, oligonucleotides, and peptides, ensuring efficient, sustainable, and scientifically rigorous transitions from development to GMP-compliant manufacturing.
Driven by digital transformation, operational excellence, and the highest quality standards, we set new benchmarks in commercial-scale manufacturing for both small and large molecules.
At Syngene, we believe that investing in our people is fundamental to achieving scientific excellence.
Total Workforce
New Joinees
Scientists
PhD Scientists
Hours of mandatory and technical training
At Syngene, we drive meaningful change through CSR initiatives in Healthcare, Science Education, Research and Scholarships, and Environmental Sustainability, thus empowering underserved communities in partnership with the Biocon Foundation and the Biocon Academy.
With evolving global dynamics, we continue to deliver faster, strengthen our sourcing ecosystem, diversify supply chain risks, and drive cost competitiveness, all while integrating highest standards of compliance into our procurement framework.
In FY25, Syngene focused on enhancing its digital and IT capabilities through strategic initiatives aimed at driving innovation and operational excellence. The IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.
At Syngene, quality drives efficiency, innovation and competitive advantage. Our proactive approach combines robust systems, advanced technology, and a culture of excellence to ensure precision in every process.
We take our responsibility to people and the planet seriously. By using resources wisely and raising operational standards, we’re building a safer, more sustainable, and efficient future for all.
At Syngene, excellence is a core value that guides everything we do. Driven by a commitment to continuous improvement, we aim to consistently deliver value and delight our customers through strong project management, service delivery, and operational excellence.
Pharmaceutical Development of a Broad-Spectrum Antibacterial Candidate for Multidrug-Resistant Infections
